Major tumor regression after paclitaxel and carboplatin polychemotherapy in a patient with advanced penile cancer

Urology. 2004 Apr;63(4):778-80. doi: 10.1016/j.urology.2003.12.026.

Abstract

Penile cancer is rare in Western countries. High-risk patients are considered for prophylactic inguinal lymphadenectomy. For advanced disease, a triplet drug regimen consisting of bleomycin, methotrexate, and cisplatin is the most active combination tested so far. A 62-year-old man with penile cancer underwent partial penile amputation but presented 10 months later with inguinal nodal metastasis. He received three cycles of paclitaxel/carboplatin with marked clinical and radiologic (computed tomography and positron emission tomography) tumor regression. Later, complete resection of the inguinal nodal metastasis was performed. The paclitaxel/carboplatin combination has potential activity in penile cancer. Positron emission tomography may be used for screening of nodal metastases.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents, Phytogenic / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carboplatin / therapeutic use*
  • Carcinoma, Squamous Cell / drug therapy*
  • Carcinoma, Squamous Cell / pathology
  • Combined Modality Therapy
  • Fluorodeoxyglucose F18
  • Humans
  • Lymph Node Excision / methods
  • Lymph Nodes / diagnostic imaging
  • Lymph Nodes / pathology
  • Lymph Nodes / surgery
  • Lymphatic Metastasis / diagnostic imaging*
  • Lymphatic Metastasis / pathology
  • Male
  • Middle Aged
  • Paclitaxel / therapeutic use*
  • Penile Neoplasms / drug therapy*
  • Penile Neoplasms / pathology
  • Penile Neoplasms / surgery
  • Penis / surgery
  • Remission Induction / methods
  • Survival Analysis
  • Tomography, Emission-Computed

Substances

  • Antineoplastic Agents, Phytogenic
  • Fluorodeoxyglucose F18
  • Carboplatin
  • Paclitaxel